Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of paediatric autoimmune cytopenia and inflammatory bowel disease suggests a common genetic origin.

British journal of haematology·2024
Same author

Outcomes of lung transplantation for pleuroparenchymal fibroelastosis: A French multicentric retrospective study.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2024
Same author

IVIg therapy in the management of BK virus infections in pediatric kidney transplant patients.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2023
Same author

[Follow-up strategies for lung transplant recipients in France].

Revue des maladies respiratoires·2023
Same author

Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

[Autoinflammatory diseases associated with RIPK1 mutations: A review of the literature].

La Revue de medecine interne·2022
Same journal

[Respiratory Medicine and Research: The new SPLF's anglophone journal].

Revue de pneumologie clinique·2018
Same journal

[Medical journals publication: Let's change].

Revue de pneumologie clinique·2018
Same journal

[Multiple ulcerated tracheobronchial mucosal lesions in the eosinophilic granulomatosis with polyangiitis].

Revue de pneumologie clinique·2018
Same journal

[Medium and long-term respiratory outcome in patients operated from congenital diaphragmatic hernia: From a series of 56 patients].

Revue de pneumologie clinique·2018
Same journal

[Sporadic lymphangioleiomyomatosis: A rare cause of bilateral spontaneous pneumothorax in young woman].

Revue de pneumologie clinique·2018
Same journal

[COPD and smoking cessation: Patients' expectations and responses of health professionals].

Revue de pneumologie clinique·2018
See all related articles

Related Experiment Video

Updated: May 29, 2026

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
12:04

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

[The lungs and immunosuppressants: practical problems].

C Picard1

  • 1Service de Pneumologie et Transplantation Pulmonaire, Hôpital Foch, 40, rue Worth, 92150 Suresnes, France. c.picard@hopital-foch.org

Revue De Pneumologie Clinique
|September 17, 2011
PubMed
Summary
This summary is machine-generated.

Immunosuppressive drugs pose unique respiratory challenges for patients with pre-existing lung conditions. This review details interactions and management strategies for respiratory complications in these patients.

More Related Videos

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
12:04

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Increasing use of immunosuppressive drugs presents novel challenges for lung specialists.
  • Patients on immunosuppressants are at higher risk for respiratory complications.

Purpose of the Study:

  • To review specific interactions between pre-existing respiratory diseases and immunosuppressants.
  • To discuss management of respiratory complications in patients receiving immunosuppressive therapy.

Main Methods:

  • Literature review of pre-existing respiratory diseases and immunosuppressants.
  • Analysis of respiratory complications in immunosuppressed patients.

Main Results:

  • Identified specific interactions between conditions like asthma, bronchiectasis, and infiltrative lung disease with immunosuppressants.
  • Highlighted key issues in managing infections, thoracic surgery, neoplasia, and thromboembolism in this patient group.

Conclusions:

  • Lung specialists must be aware of the complex interplay between immunosuppression and respiratory health.
  • Proactive management strategies are crucial for optimizing outcomes in immunosuppressed patients with lung disease.